LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

AstraZeneca shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior ...

AstraZeneca shared the topline result ... developed by Array BioPharma before AZ licensed the drug in 2003. The MEK 1/2 ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca has upgraded ... supported by double-digit percentage growth in lung cancer treatments Tagrisso and Imfinzi and the non-Hodgkin's lymphoma drug Calquence. Trading further benefited ...